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Background Clinical Case
• Aplastic anemia with incidence of an estimated two per million in 
Western countries.
• Rare hematological disease characterized by pancytopenia and a 
profoundly hypocellular bone marrow. 
• Exact pathophysiology unknown but activation of cytotoxic T-cells 
which inappropriately target antigens on hematopoietic stem cells 
thought to play a role. 
• Known to be induced by viral infections in particular HIV and the 
hepatitis viruses.
• Second known adult case of aplastic anemia following infection with the 
SARS-Co-V-2 virus.
•40-year-old Hispanic female with BMI 32, pre-diabetes and history of 
papillary thyroid cancer s/p left hemithyroidectomy.
•Presented with lower limb petechiae 10 days following resolution of 
symptoms from confirmed SARS-Co-V-2 infection. 
•Initial laboratory workup revealed pancytopenia.
•ITP first suspected and treatment with dexamethasone and IVIG failed to 
produce an improvement in the pancytopenia.
•Subsequent bone marrow was performed, confirming diagnosis of severe 
aplastic anemia.
Figure 2: Bone marrow biopsy with hypocellular marrow (<5%) with focal residual hematopoietic cellular 
elements
Workup/Results
• Patient age precluded her from allogenic stem cell transplant as first line 
treatment.
• Started on immunosuppressive therapy with anti-thymocyte globulin 
(ATG), cyclosporine (CSA), and prednisone.
• Initial therapy with the thrombopoeitin agonist, eltrombopag, was not 
possible due to lack of insurance and immigration status.
• Failed to respond to immunosuppressive therapy remaining pancytopenic
with multiple admission with febrile neutropenia.
• Suffered severe hyperbilirubinemia secondary to cyclosporine, requiring 
dose reduction.
• Thrombopoeitin agonist, eltrombopag started at 150mg daily.
• Eventually had response with HLA matched platelet transfusion.
• Most recently had Hgb 7.5g/dL, platelets of 14 x109/L, WCC 2.6 x 109/L, 
neutrophils of 1.5 x 109/L
Treatment Progress
• Adds to the growing literature of the side effects of SARS-Co-V-2 infection.
• Illustrates that the bone marrow can also be targeted as a result of the cytokine storms associated with the morbidity and mortality of SARS-Co-V-2.
• Adds to our understanding of the array of viruses that can be implicated in the development of aplastic anemia.
• Highlights the complexities of providing evidenced based care for patients without health insurance and legal documentation during a global 
pandemic, which further widens the inequities in outcomes following infection with this novel virus.
Conclusion
Liuand Apheresis Science, p.102, C., Sun, Y. and Shao, Z., 2019. Current Concepts of the Pathogenesis of Aplastic Anemia. Current Pharmaceutical Design, 25(3), pp.236-241.
Tao, W., Shengchao, K., Wei, F., Hua, F., Xinhua, Z., Xiaojing, W., Peijun, D., Tonghui, W., Hai, B., Rui, X., Qian, Z., Xin, X. and Dawei, X., 2020. A case report of aplastic anemia accompanied with COVID-19. Chinese Journal of 
Hematology, 41(4).




Platelets 5 x 109/L
WCC 2 x 109/L








HIV ½ Ab and P24 
Ag
Non-reactive
Hepatitis B Surface 
Ag
Non-reactive
Hepatitis C Ab Non-reactive
Figure 1: Lower limb petechiae
• Peripheral smear: Pancytopenia with morphologically normal platelets, leukocytes, and red blood cells. No atypical lymphoid cells, overtly 
dysplastic granulocytes, immature monocytes or blasts are seen.
• Flow cytometry on BM aspirate: phenotypically normal T-cells, not immunophenotypically in keeping with non-Hodgkin lymphoma.
• Immunostaining negative for parvovirus-19
• Flow cytometry negative for paroxysmal nocturnal hemoglobinuria (PNH).
